Risk of Secondary Pelvic Cancers Following Radiotherapy for Prostate Cancer
Cancers · 24.07.2026 · 18 (15) · 2382
DOI: 10.3390/cancers18152382 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 24.07.2026. Verfasst von Mutlay Sayan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Secondary pelvic cancer (SC) risk after radiotherapy (RT) for prostate cancer (PC) remains uncertain; we performed an updated synthesis of observational studies and randomized trials.
Methods
We reviewed systematic reviews, meta-analyses, and randomized trials published in 2001–2025 evaluating SC risk after RT for PC. Given potential detection bias from RT-related rectal or bladder bleeding, the primary outcome was relative risk (RR) of death.
Results
Across 12 reports—eight systematic reviews/meta-analyses and four randomized trials—comparators were predominantly RP or mixed cohorts; review-level sample sizes were not summed because of potential overlap. In randomized data with >10 years of follow-up, SC occurred in 25.3% of RT-treated patients versus 20.8% in RP/hormone therapy groups, while deaths from other cancers occurred in 8.5% versus 7.2%. The median converted RR of death from SC was 1.05. These estimates may be influenced by unmeasured lifestyle factors such as smoking and baseline comorbidities, which were not accounted for in observational cohorts and are more common among patients receiving RT, who are often less likely to be RP candidates.
Conclusions
RT is associated with a small but consistent increase in SC, with a 4.5% absolute excess incidence over >10 years. The observed 1.3% absolute difference in deaths from other cancers was modest and similar in magnitude to the reported perioperative mortality range of approximately 0.2–1.1% after RP, although these risks occur over substantially different time horizons. The smaller excess seen in randomized trials than in retrospective studies suggests that much of the apparent risk in prior reports may reflect confounding and/or detection bias rather than direct radiation effect.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
- Department of Statistics, Ankara University, Ankara 06100, Türkiye.
- Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143, USA.
- Department of Radiation Oncology, City of Hope Cancer Center, Duarte, CA 91010, USA.
- Division of Urology, Howard University College of Medicine, Washington, DC 20059, USA.
ORCID-Profile: Mutlay Sayan, Yetkin Tuac, Yun Rose Li, Pamela W Coleman
Zitieren
APA
Sayan, M., Tuac, Y., Hernandez, C., Li, Y. R., Coleman, P. W., & Roach, M. (2026). Risk of Secondary Pelvic Cancers Following Radiotherapy for Prostate Cancer. Cancers, 18(15), 2382. https://doi.org/10.3390/cancers18152382
Vancouver
Sayan M, Tuac Y, Hernandez C, Li YR, Coleman PW, Roach M. Risk of Secondary Pelvic Cancers Following Radiotherapy for Prostate Cancer. Cancers. 2026;18(15):2382. doi:10.3390/cancers18152382
BibTeX
@article{Sayan2026,
author = {Sayan, Mutlay and Tuac, Yetkin and Hernandez, Crystal and Li, Yun Rose and Coleman, Pamela W and Roach, Mack},
title = {Risk of Secondary Pelvic Cancers Following Radiotherapy for Prostate Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {15},
pages = {2382},
doi = {10.3390/cancers18152382}
}
EUVIMED